Utilizing a Combined Vision Transformer and Traditional Radiomics Approach to Forecast Central Lymph Node Metastasis in Papillary Thyroid Carcinoma via Dynamic Dual-Modality Ultrasound - Takeaways - MDSpire

Utilizing a Combined Vision Transformer and Traditional Radiomics Approach to Forecast Central Lymph Node Metastasis in Papillary Thyroid Carcinoma via Dynamic Dual-Modality Ultrasound

  • By

  • Peng-Fei Zhu

  • Xiao-Feng Zhang

  • Yu-Xiang Mao

  • Pu Zhou

  • Jian-Jun Lin

  • Long Shi

  • Xin-Wu Cui

  • Ying He

  • January 26, 2026

  • 0 min

Share

  • 1

    Papillary thyroid carcinoma (PTC) accounts for 85%-95% of thyroid cancer cases, with 30%-80% prone to central lymph node metastasis (CLNM).

  • 2

    Conventional ultrasound has a sensitivity of less than 40% for detecting CLNM, highlighting the need for improved diagnostic methods.

  • 3

    The study combines B-mode ultrasound and superb microvascular imaging to enhance diagnostic accuracy for predicting CLNM in PTC patients.

  • 4

    A fusion model integrating radiomics and Vision Transformer features will be developed to capture tumor characteristics effectively.

  • 5

    The study utilizes a retrospective analysis of 310 PTC patients to validate the predictive performance of the proposed dual-modality ultrasound approach.

Original Source(s)

Utilizing a Combined Vision Transformer and Traditional Radiomics Approach to Forecast Central Lymph Node Metastasis in Papillary Thyroid Carcinoma via Dynamic Dual-Modality Ultrasound

  • by Peng-Fei Zhu, Xiao-Feng Zhang, Yu-Xiang Mao, Pu Zhou, Jian-Jun Lin, Long Shi, Xin-Wu Cui, Ying He

  • January 26, 2026

Related Content

Correction: MRI-based habitat radiomics for predicting WHO/ISUP nuclear grade in clear cell renal cell carcinoma

Colorectal Cancer Treatment During Pregnancy

Colorectal cancer (CRC) impacts about 1 in 13,000 pregnancies in the United States. This article follows the case of a 36-year-old woman diagnosed with CRC while pregnant and highlights considerations around CRC diagnosis and cancer treatment during pregnancy.

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.